KR102780496B1 - 종양용해성 바이러스에 의한 PTEN-Long의 발현 - Google Patents

종양용해성 바이러스에 의한 PTEN-Long의 발현 Download PDF

Info

Publication number
KR102780496B1
KR102780496B1 KR1020197005487A KR20197005487A KR102780496B1 KR 102780496 B1 KR102780496 B1 KR 102780496B1 KR 1020197005487 A KR1020197005487 A KR 1020197005487A KR 20197005487 A KR20197005487 A KR 20197005487A KR 102780496 B1 KR102780496 B1 KR 102780496B1
Authority
KR
South Korea
Prior art keywords
cells
pten
cell
cancer
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197005487A
Other languages
English (en)
Korean (ko)
Other versions
KR20190035782A (ko
Inventor
발벤 카우르
루크 루셀
Original Assignee
오하이오 스테이트 이노베이션 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오하이오 스테이트 이노베이션 파운데이션 filed Critical 오하이오 스테이트 이노베이션 파운데이션
Publication of KR20190035782A publication Critical patent/KR20190035782A/ko
Application granted granted Critical
Publication of KR102780496B1 publication Critical patent/KR102780496B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020197005487A 2016-07-29 2017-07-31 종양용해성 바이러스에 의한 PTEN-Long의 발현 Active KR102780496B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368822P 2016-07-29 2016-07-29
US62/368,822 2016-07-29
US201762479671P 2017-03-31 2017-03-31
US62/479,671 2017-03-31
PCT/US2017/044683 WO2018023114A1 (en) 2016-07-29 2017-07-31 Expression of pten-long with ocolytic viruses

Publications (2)

Publication Number Publication Date
KR20190035782A KR20190035782A (ko) 2019-04-03
KR102780496B1 true KR102780496B1 (ko) 2025-03-11

Family

ID=61016870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005487A Active KR102780496B1 (ko) 2016-07-29 2017-07-31 종양용해성 바이러스에 의한 PTEN-Long의 발현

Country Status (8)

Country Link
US (2) US20200085890A1 (cg-RX-API-DMAC10.html)
EP (2) EP4403229A3 (cg-RX-API-DMAC10.html)
JP (3) JP7638061B2 (cg-RX-API-DMAC10.html)
KR (1) KR102780496B1 (cg-RX-API-DMAC10.html)
CN (1) CN110087662A (cg-RX-API-DMAC10.html)
AU (1) AU2017301901B2 (cg-RX-API-DMAC10.html)
SG (1) SG11201900815UA (cg-RX-API-DMAC10.html)
WO (1) WO2018023114A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
EP3529347A1 (en) 2016-10-19 2019-08-28 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
SG11202101581RA (en) * 2017-08-09 2021-03-30 Ohio State Innovation Foundation Oncolytic virus carrying e-cadherin and uses thereof
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN114900773A (zh) 2017-12-14 2022-08-12 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
CN108484780A (zh) * 2018-04-16 2018-09-04 河南大学 一种融合蛋白PTEN-L-p53及其应用
US20220169997A1 (en) * 2019-04-12 2022-06-02 Therapten Biosciences Inc. Compositions and methods to manufacture tumor suppressor fusions
KR20220038485A (ko) * 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
CN111763260B (zh) * 2020-06-11 2022-03-29 四川大学华西医院 一种PTEN-Long多克隆抗体及其制备方法和用途
WO2024163335A2 (en) * 2023-01-30 2024-08-08 The Board Of Regents Of The University Of Texas System Pten gene therapy vectors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522168A (ja) 2010-02-17 2013-06-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 分子の膜通過送達のためのｐｔｅｎロングリーダー配列の使用
JP2015231372A (ja) * 2009-02-17 2015-12-24 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 腫瘍の治療に使用できるｐｔｅｎの細胞外形態の同定

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (cg-RX-API-DMAC10.html) 1968-10-17 1970-08-24
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6261834B1 (en) 1991-11-08 2001-07-17 Research Corporation Technologies, Inc. Vector for gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
US8658778B2 (en) * 2005-03-09 2014-02-25 Board Of Regents, The University Of Texas System hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
EP2563919B1 (en) * 2010-04-26 2018-06-13 Green Cross Corporation Tumor-specific promoter and oncolytic virus vector comprising the same
EP2494978A1 (en) * 2011-03-03 2012-09-05 Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses
US9863935B2 (en) * 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy
US20160060652A1 (en) 2013-03-13 2016-03-03 Lapian's Corp Microvesicle and method for producing the same
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
GB201408297D0 (en) * 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015231372A (ja) * 2009-02-17 2015-12-24 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 腫瘍の治療に使用できるｐｔｅｎの細胞外形態の同定
JP2013522168A (ja) 2010-02-17 2013-06-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 分子の膜通過送達のためのｐｔｅｎロングリーダー配列の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLoS ONE, Vol.7, No.4, e35153(2012.04.11.)*

Also Published As

Publication number Publication date
AU2017301901B2 (en) 2024-08-29
EP3490574A1 (en) 2019-06-05
EP3490574B1 (en) 2024-05-22
EP4403229A3 (en) 2024-08-14
US20230338443A1 (en) 2023-10-26
JP2024123088A (ja) 2024-09-10
JP2019523008A (ja) 2019-08-22
JP7638061B2 (ja) 2025-03-03
CN110087662A (zh) 2019-08-02
SG11201900815UA (en) 2019-02-27
EP4403229A2 (en) 2024-07-24
WO2018023114A1 (en) 2018-02-01
KR20190035782A (ko) 2019-04-03
JP2022163182A (ja) 2022-10-25
AU2017301901A1 (en) 2019-02-21
EP3490574B8 (en) 2024-07-10
EP3490574A4 (en) 2020-03-04
CA3032412A1 (en) 2018-02-01
US20200085890A1 (en) 2020-03-19
BR112019001737A2 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
US20230338443A1 (en) Expression of pten-long with oncolytic viruses
US20240000822A1 (en) Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US20180201921A1 (en) CRISPRs
US20190038770A1 (en) Rna guided eradication of human jc virus and other polyomaviruses
US20120027725A1 (en) Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules to treat liver cancer
US20230048681A1 (en) Compositions and methods of treatment for lytic and lysogenic viruses
US20220290177A1 (en) Compositions and methods for excision with single grna
US12357704B2 (en) Tailored hypoimmune nanovesicular delivery systems for cancer tumors
US20180208914A1 (en) Lentivirus and non-integrating lentivirus as viral vector to deliver crispr therapeutic
EP3788070A1 (en) Compositions and methods for hemoglobin production
JP2024502295A (ja) 遺伝子治療において交流電場を使用するための方法及び組成物
CA3032412C (en) Expression of pten-long with oncolytic viruses
HK40114297A (en) Expression of pten-long with oncolytic viruses
US20190071673A1 (en) CRISPRs WITH IMPROVED SPECIFICITY
HK40004120A (en) Expression of pten-long with ocolytic viruses
HK40004120B (en) Expression of pten-long with ocolytic viruses
BR112019001737B1 (pt) Vírus herpes simplex (hsv) oncolítico recombinante compreendendo um gene pten-long e seu uso para inibição da metástase de um câncer
WO2017070113A1 (en) Pharmaceutical composition comprising nanog shrna, and method of using nanog shrna to treat cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200730

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221019

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230616

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240115

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230616

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20221019

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20240115

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230915

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20230220

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200730

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240718

Patent event code: PE09021S01D

PX0701 Decision of registration after re-examination

Patent event date: 20250203

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250307

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250307

End annual number: 3

Start annual number: 1

PG1601 Publication of registration